Shock, Septic

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
SevofluranePhase 21 trial
Active Trials
NCT03643367Not Yet RecruitingEst. Nov 2027
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
PhysostigmineN/A1 trial
Active Trials
NCT03013322Completed20Est. Feb 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
City TherapeuticsSevoflurane
Heidelberg PharmaPhysostigmine

Clinical Trials (2)

Total enrollment: 20 patients across 2 trials

NCT03643367City TherapeuticsSevoflurane

Sevoflurane Sedation in Patients With Septic Shock

Start: Jan 2026Est. completion: Nov 2027
Phase 2Not Yet Recruiting
NCT03013322Heidelberg PharmaPhysostigmine

Anticholium® Per Se

Start: Jan 2015Est. completion: Feb 201720 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space